探索美国和欧洲的迷幻剂监管框架

IF 3.8 4区 医学 Q1 PSYCHIATRY
Hitesh Kumar Behera , Ramesh Joga , Sravani Yerram , Praveena Karnati , Tejaswini Mergu , Kajal Gandhi , Sowndharya M , Deepak Nathiya , Ravindra Pal Singh , Saurabh Srivastava , Sandeep Kumar
{"title":"探索美国和欧洲的迷幻剂监管框架","authors":"Hitesh Kumar Behera ,&nbsp;Ramesh Joga ,&nbsp;Sravani Yerram ,&nbsp;Praveena Karnati ,&nbsp;Tejaswini Mergu ,&nbsp;Kajal Gandhi ,&nbsp;Sowndharya M ,&nbsp;Deepak Nathiya ,&nbsp;Ravindra Pal Singh ,&nbsp;Saurabh Srivastava ,&nbsp;Sandeep Kumar","doi":"10.1016/j.ajp.2024.104242","DOIUrl":null,"url":null,"abstract":"<div><p>Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory approvals of key psychedelic substances like psilocybin, 3,4-Methyl enedioxy methamphetamine (MDMA), mescaline, ketamine, and Lysergic acid diethylamide (LSD). It also provides an overview of legal aspects, and regulations surrounding psychedelics in the US &amp; Europe, emphasizing their Schedule I classification due to potential misuse. The United States Food &amp; Drug Administration (USFDA) closely monitors psychedelics, employing expedited pathways for evaluation. Further, recent guidance from the FDA on considerations for clinical Investigations supports the safe development of psychedelics for human welfare. European Medicines Agency (EMA) regulators focus on atypical psychedelics, addressing challenges in safety and efficacy. Marketed products, such as Spravato nasal spray, face limited distribution due to safety concerns. The call for careful regulation and legislation is essential for harnessing psychedelics' potential for therapeutic benefits and human welfare.</p></div>","PeriodicalId":8543,"journal":{"name":"Asian journal of psychiatry","volume":"102 ","pages":"Article 104242"},"PeriodicalIF":3.8000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring the regulatory framework of psychedelics in the US & Europe\",\"authors\":\"Hitesh Kumar Behera ,&nbsp;Ramesh Joga ,&nbsp;Sravani Yerram ,&nbsp;Praveena Karnati ,&nbsp;Tejaswini Mergu ,&nbsp;Kajal Gandhi ,&nbsp;Sowndharya M ,&nbsp;Deepak Nathiya ,&nbsp;Ravindra Pal Singh ,&nbsp;Saurabh Srivastava ,&nbsp;Sandeep Kumar\",\"doi\":\"10.1016/j.ajp.2024.104242\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory approvals of key psychedelic substances like psilocybin, 3,4-Methyl enedioxy methamphetamine (MDMA), mescaline, ketamine, and Lysergic acid diethylamide (LSD). It also provides an overview of legal aspects, and regulations surrounding psychedelics in the US &amp; Europe, emphasizing their Schedule I classification due to potential misuse. The United States Food &amp; Drug Administration (USFDA) closely monitors psychedelics, employing expedited pathways for evaluation. Further, recent guidance from the FDA on considerations for clinical Investigations supports the safe development of psychedelics for human welfare. European Medicines Agency (EMA) regulators focus on atypical psychedelics, addressing challenges in safety and efficacy. Marketed products, such as Spravato nasal spray, face limited distribution due to safety concerns. The call for careful regulation and legislation is essential for harnessing psychedelics' potential for therapeutic benefits and human welfare.</p></div>\",\"PeriodicalId\":8543,\"journal\":{\"name\":\"Asian journal of psychiatry\",\"volume\":\"102 \",\"pages\":\"Article 104242\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian journal of psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1876201824003356\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian journal of psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876201824003356","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

迷幻药物疗法因其在治疗抑郁症、创伤后应激障碍(PTSD)和焦虑症等各种精神疾病方面的潜力而备受瞩目。迷幻治疗在作用方式、法律地位和治疗方法上都有别于传统的精神病治疗方法。本著作深入探讨了主要迷幻药物的治疗潜力、机制和监管批准情况,如迷幻素、3,4-甲基二氧甲基苯丙胺(MDMA)、麦司卡林、氯胺酮和麦角酰二乙胺(LSD)。报告还概述了美国和欧洲有关迷幻药的法律和法规,强调了迷幻药因可能被滥用而被列入附表 I 的情况。美国食品和药物管理局(USFDA)密切监控迷幻剂,并采用快速评估途径。此外,美国食品和药物管理局最近发布的临床研究注意事项指南也支持为人类福祉安全开发迷幻剂。欧洲药品管理局(EMA)的监管机构重点关注非典型迷幻药,应对安全性和有效性方面的挑战。市场上销售的产品,如 Spravato 鼻用喷雾剂,由于安全问题,销售受到限制。呼吁谨慎监管和立法对于利用迷幻剂的潜在治疗功效和人类福祉至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring the regulatory framework of psychedelics in the US & Europe

Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory approvals of key psychedelic substances like psilocybin, 3,4-Methyl enedioxy methamphetamine (MDMA), mescaline, ketamine, and Lysergic acid diethylamide (LSD). It also provides an overview of legal aspects, and regulations surrounding psychedelics in the US & Europe, emphasizing their Schedule I classification due to potential misuse. The United States Food & Drug Administration (USFDA) closely monitors psychedelics, employing expedited pathways for evaluation. Further, recent guidance from the FDA on considerations for clinical Investigations supports the safe development of psychedelics for human welfare. European Medicines Agency (EMA) regulators focus on atypical psychedelics, addressing challenges in safety and efficacy. Marketed products, such as Spravato nasal spray, face limited distribution due to safety concerns. The call for careful regulation and legislation is essential for harnessing psychedelics' potential for therapeutic benefits and human welfare.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Asian journal of psychiatry
Asian journal of psychiatry Medicine-Psychiatry and Mental Health
CiteScore
12.70
自引率
5.30%
发文量
297
审稿时长
35 days
期刊介绍: The Asian Journal of Psychiatry serves as a comprehensive resource for psychiatrists, mental health clinicians, neurologists, physicians, mental health students, and policymakers. Its goal is to facilitate the exchange of research findings and clinical practices between Asia and the global community. The journal focuses on psychiatric research relevant to Asia, covering preclinical, clinical, service system, and policy development topics. It also highlights the socio-cultural diversity of the region in relation to mental health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信